Ariella Evenzahav is head of US Oncology Market Research and Analytics at Takeda. Prior to holding this position, she was an independent consultant, where she partnered with a number of different pharmaceutical companies to help drive commercial strategies of oncology drugs in various phases of development She has years of experience in commercial oncology drug development in various functions. Prior to consulting, Dr. Evenzahav was Director of Commercial Operations, Oncology at Pfizer Inc, where her responsibilities included, among others, ensuring delivery of accurate and actionable commercial development plans and forecasts for the oncology portfolio as well as alignment among teams representing the individual oncology drugs. Dr. Evenzahav oversaw the commercial development of the early oncology pipeline as well as drugs in later development stages for the treatment of malignant melanoma, glioblastoma, breast cancer, and lung cancer. She also completed a number of commercial evaluations for licensing and acquisition opportunities in the oncology space. She was the commercial lead on the hematological tumor strategy team and was responsible for assessing areas of unmet need in the hematologic tumor space and identifying potential candidates from Pfizer's pipeline which might meet those needs. She holds a BS from Brown University and a PhD in Bio-organic Chemistry from Columbia University.